IAPP and Alzheimer disease 3: Although non-aggregating IAPP-based peptides such as pramlintide, has received significant interest in developing treatment strategies for AD3,31,48–50, they can have a tendency to form fibrils48 and also cross-seed with Aβ that may have undesirable effects31.